Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

Conditions: Progressive Supranuclear Palsy Interventions: Drug: GV1001 Placebo; Drug: GV1001 1.12mg Sponsors: GemVax& Kael Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials